Global Pressurized Metered Dose Inhaler Market Growth 2023-2029

Global Pressurized Metered Dose Inhaler Market Growth 2023-2029

A metered-dose inhaler (MDI) is a device that delivers a specific amount of medication to the lungs, in the form of a short burst of aerosolized medicine that is usually self-administered by the patient via inhalation. It is the most commonly used delivery system for treating asthma, chronic obstructive pulmonary disease (COPD) and other respiratory diseases. The medication in a metered dose inhaler is most commonly a bronchodilator, corticosteroid or a combination of both for the treatment of asthma and COPD. Other medications less commonly used but also administered by MDI are mast cell stabilizers, such as cromoglicate or nedocromil.
LPI (LP Information)' newest research report, the “Pressurized Metered Dose Inhaler Industry Forecast” looks at past sales and reviews total world Pressurized Metered Dose Inhaler sales in 2022, providing a comprehensive analysis by region and market sector of projected Pressurized Metered Dose Inhaler sales for 2023 through 2029. With Pressurized Metered Dose Inhaler sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Pressurized Metered Dose Inhaler industry.
This Insight Report provides a comprehensive analysis of the global Pressurized Metered Dose Inhaler landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Pressurized Metered Dose Inhaler portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Pressurized Metered Dose Inhaler market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Pressurized Metered Dose Inhaler and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Pressurized Metered Dose Inhaler.
The global Pressurized Metered Dose Inhaler market size is projected to grow from US$ 5899.6 million in 2022 to US$ 7572.6 million in 2029; it is expected to grow at a CAGR of 7572.6 from 2023 to 2029.
The classification of Pressurized Metered Dose Inhaler includes manual type and smart type. The proportion of manual type in 2019 is about 99%. But the smart metered-dose inhaler will have a much higher growth rate in the future.
Pressurized Metered Dose Inhaler is widely used for Asthma, COPD and Others. The most proportion of Pressurized Metered Dose Inhaler used for Asthma, and the proportion in 2019 is about 48.94%.
North America is the largest market, with a market share nearly 44.49% in 2019. Following North America, Europe is the second largest sales place with the sales market share of 26.40%.
Market competition is intense. GlaxoSmithKline, Chiesi Farmaceutici S.p.A, AstraZeneca, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers.
This report presents a comprehensive overview, market shares, and growth opportunities of Pressurized Metered Dose Inhaler market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Manual Pressurized Metered Dose Inhaler
Smart Pressurized Metered Dose Inhaler
Segmentation by application
Asthma
COPD
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
GlaxoSmithKline
Chiesi Farmaceutici S.p.A
AstraZeneca
Teva
Merck & Co. Inc
Boehringer Ingelheim
Mylan
Arkon

Key Questions Addressed in this Report
What is the 10-year outlook for the global Pressurized Metered Dose Inhaler market?
What factors are driving Pressurized Metered Dose Inhaler market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Pressurized Metered Dose Inhaler market opportunities vary by end market size?
How does Pressurized Metered Dose Inhaler break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?

Please note: The report will take approximately 2 business days to prepare and deliver.